H.C. Wainwright maintains buy rating on Candel Therapeutics
ArchivedSingle Source|1 articles|1 sources|1 blocks
Detected: Updated: Analyzed:
Reported Facts
Observable data points shared across all narratives
- •H.C. Wainwright is an investment firm providing stock ratings.
- •The buy rating on Candel Therapeutics was reiterated on March 13, 2026.
- •Candel Therapeutics is a company listed on the stock market.
- •The rating suggests positive expectations for Candel Therapeutics' stock performance.
What Could Happen If...
- ▸If H.C. Wainwright upgrades Candel Therapeutics to a strong buy investor demand for Candel Therapeutics shares could increase, potentially raising the stock price
Market Exposure
StocksCandel TherapeuticsUpward Pressure
The reiterated buy rating by H.C. Wainwright may encourage investors to purchase shares, increasing demand and potentially raising the stock price.
This is not investment advice. Market exposure is based on conditional event analysis.
Key Actors
Instruments
Organizations
Source Coverage
FINANCE
1 articles
More coverage on this story
- More on Candel Therapeutics
- More on Candel Therapeutics
- More on H.C. Wainwright
Signals
Single-block coverage
Related Events
▸H.C. Wainwright Maintains Buy Rating on Sanara MedTech SharesArchived▸H.C. Wainwright Maintains Zentalis Rating After Ovarian Cancer DataArchived▸H.C. Wainwright Reiterates Buy Rating on Compass Pathways StockArchived▸H.C. Wainwright Maintains Buy Rating on Kyverna TherapeuticsArchived▸H.C. Wainwright lowers Evommune price target over dilution concerns